Terms: = Prostate cancer AND ER, estrogen receptor AND Treatment
532 results:
1. The Predictive Role of Serum Lipid Levels, p53 and ki-67, According to Molecular Subtypes in Breast cancer: A Randomized Clinical Study.
Faur IF; Dobrescu A; Clim IA; Pasca P; Prodan-Barbulescu C; Tarta C; Neamtu AA; Brebu D; Neamtu C; Rosu M; Duta C; Clim A; Lazar G; Totolici B
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612725
[TBL] [Abstract] [Full Text] [Related]
2. Novel estrogen receptor β/histone deacetylase dual-targeted near-infrared fluorescent probes as theranostic agents for imaging and treatment of prostate cancer.
He P; Yu H; Deng X; Xin L; Xu B; Zhou HB; Dong C
Eur J Med Chem; 2024 Mar; 268():116236. PubMed ID: 38367494
[TBL] [Abstract] [Full Text] [Related]
3. treatments Targeting the Androgen receptor and Its Splice Variants in Breast cancer.
Tien AH; Sadar MD
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339092
[TBL] [Abstract] [Full Text] [Related]
4. Raltitrexed induces apoptosis through activating ROS-mediated ER stress by impeding HSPA8 expression in prostate cancer cells.
Tao Y; Lu J; Li L; Lu L; Fu B; Zhang J; Zhang S; Ma R; Ma J; Sun J; Fu S; Liu S; Wang Z
Biochim Biophys Acta Mol Cell Res; 2024 Mar; 1871(3):119684. PubMed ID: 38301906
[TBL] [Abstract] [Full Text] [Related]
5. New mode of action of curcumin on prostate cancer cells: Modulation of endoplasmic reticulum-associated degradation mechanism and estrogenic signaling.
Erzurumlu Y; Dogan HK; Catakli D
J Biochem Mol Toxicol; 2024 Jan; 38(1):e23636. PubMed ID: 38229314
[TBL] [Abstract] [Full Text] [Related]
6. ER-positive and BRCA2-mutated breast cancer: a literature review.
Li PC; Zhu YF; Cao WM; Li B
Eur J Med Res; 2024 Jan; 29(1):30. PubMed ID: 38184581
[TBL] [Abstract] [Full Text] [Related]
7. Structure based docking and biological evaluation towards exploring potential anti-cancerous and apoptotic activity of 6-Gingerol against human prostate carcinoma cells.
Khan H; Azad I; Arif Z; Parveen S; Kumar S; Rais J; Ansari JA; Nasibullah M; Kumar S; Arshad M
BMC Complement Med Ther; 2024 Jan; 24(1):8. PubMed ID: 38166796
[TBL] [Abstract] [Full Text] [Related]
8. Therapeutic, diagnostic and prognostic values of TRIM proteins in prostate cancer.
Li X; Bai Y; Feng K; Chu Z; Li H; Lin Z; Tian L
Pharmacol Rep; 2023 Dec; 75(6):1445-1453. PubMed ID: 37921966
[TBL] [Abstract] [Full Text] [Related]
9. Androgen deprivation therapy caused a drastic proliferation of B-cell lymphoma with IgG4-related disease in patients with prostate cancer: a case report.
Sasagawa H; Numakura K; Mori M; Kobayashi M; Kashima S; Yamamoto R; Nara T; Saito M; Narita S; Nanjo H; Habuchi T
J Cancer Res Clin Oncol; 2023 Nov; 149(16):15091-15094. PubMed ID: 37688628
[TBL] [Abstract] [Full Text] [Related]
10. Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis.
Dahut M; Fousek K; Horn LA; Angstadt S; Qin H; Hamilton DH; Schlom J; Palena C
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37678915
[TBL] [Abstract] [Full Text] [Related]
11. Dependency of Tamoxifen Sensitive and Resistant ER
Bhasin S; Dusek C; Peacock JW; Cherkasov A; Wang Y; Gleave M; Ong CJ
Cells; 2023 Jun; 12(13):. PubMed ID: 37443749
[TBL] [Abstract] [Full Text] [Related]
12. Relative Burden of cancer and Noncancer Mortality Among Long-Term Survivors of Breast, prostate, and Colorectal cancer in the US.
Kc M; Fan J; Hyslop T; Hassan S; Cecchini M; Wang SY; Silber A; Leapman MS; Leeds I; Wheeler SB; Spees LP; Gross CP; Lustberg M; Greenup RA; Justice AC; Oeffinger KC; Dinan MA
JAMA Netw Open; 2023 Jul; 6(7):e2323115. PubMed ID: 37436746
[TBL] [Abstract] [Full Text] [Related]
13. Targeting the ATF6-Mediated ER Stress Response and Autophagy Blocks Integrin-Driven prostate cancer Progression.
Macke AJ; Pachikov AN; Divita TE; Morris ME; LaGrange CA; Holzapfel MS; Kubyshkin AV; Zyablitskaya EY; Makalish TP; Eremenko SN; Qiu H; Riethoven JM; Hemstreet GP; Petrosyan A
Mol Cancer Res; 2023 Sep; 21(9):958-974. PubMed ID: 37314749
[TBL] [Abstract] [Full Text] [Related]
14. The impact of sarcopenia on clinical outcomes in men with metastatic castrate-resistant prostate cancer.
Papadopoulos E; Wong AKO; Law SHC; Zhang LZJ; Breunis H; Emmenegger U; Alibhai SMH
PLoS One; 2023; 18(6):e0286381. PubMed ID: 37262068
[TBL] [Abstract] [Full Text] [Related]
15. cancer-biomarkers associated with sex hormone receptors and recent therapeutic advancements: a comprehensive review.
Anbarasu S; Anbarasu A
Med Oncol; 2023 May; 40(6):171. PubMed ID: 37162589
[TBL] [Abstract] [Full Text] [Related]
16. The endocannabinoid system, a new gatekeeper in the pharmacology of human hepatocellular carcinoma.
Ebrahimi N; Far NP; Fakhr SS; Faghihkhorasani F; Miraghel SA; Chaleshtori SR; Rezaei-Tazangi F; Beiranvand S; Baziyar P; Manavi MS; Zarrabi A; Nabavi N; Ren J; Aref AR
Environ Res; 2023 Jul; 228():115914. PubMed ID: 37062475
[TBL] [Abstract] [Full Text] [Related]
17. estrogen receptors regulate galectin‑3 in androgen‑independent DU‑145 prostate cancer cells.
Souza DS; Macheroni C; Vicente CM; Cavalheiro RP; Campo VL; Porto CS
Oncol Rep; 2023 May; 49(5):. PubMed ID: 36960864
[TBL] [Abstract] [Full Text] [Related]
18. Continuity of care and advanced prostate cancer.
Jayadevappa R; Guzzo T; Vapiwala N; Malkowicz SB; Gallo JJ; Chhatre S
Cancer Med; 2023 May; 12(10):11795-11805. PubMed ID: 36951508
[TBL] [Abstract] [Full Text] [Related]
19. Hormonal and genotoxic estrogen-androgen carcinogenesis in the NBL rat prostate: A role for aromatase.
Bosland MC; Vega K; Horton L; Schlicht MJ
Prostate; 2023 Jun; 83(9):823-830. PubMed ID: 36938936
[TBL] [Abstract] [Full Text] [Related]
20. Molecular regulation of prostate cancer by Galectin-3 and estrogen receptor.
Souza DS; Macheroni C; Pereira GJS; Vicente CM; Porto CS
Front Endocrinol (Lausanne); 2023; 14():1124111. PubMed ID: 36936148
[TBL] [Abstract] [Full Text] [Related]
[Next]
